Cargando…

A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses

The aim of this study was the development of a software tool (SCRcalc) for the automatic estimation of the patient- and organ-specific cancer risk due to radiotherapy. SCRcalc was developed using the Python 3.8.7 programming language. It incorporates equations and parameters of mechanistic models fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzanis, Eleftherios, Mazonakis, Michael, Damilakis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989449/
https://www.ncbi.nlm.nih.gov/pubmed/35402031
http://dx.doi.org/10.5603/RPOR.a2022.0014
_version_ 1784683175753023488
author Tzanis, Eleftherios
Mazonakis, Michael
Damilakis, John
author_facet Tzanis, Eleftherios
Mazonakis, Michael
Damilakis, John
author_sort Tzanis, Eleftherios
collection PubMed
description The aim of this study was the development of a software tool (SCRcalc) for the automatic estimation of the patient- and organ-specific cancer risk due to radiotherapy. SCRcalc was developed using the Python 3.8.7 programming language. It incorporates equations and parameters of mechanistic models for the calculation of the organ equivalent dose (OED), the excess absolute risk (EA R) and the lifetime attributable risk (LA R) of carcinogenesis for various organs due to radiotherapy. Data from differential dose-volume histograms, as defined by a treatment planning system, could be automatically inserted into the program. Eighteen different cancer risk estimates for various organs were performed of patients subjected to radiation therapy with conventional and modulated techniques. These software estimates were compared with manual calculations. SCRcalc was developed as a standalone executable program without any dependencies. It enables direct estimations of the OED and LAR for various organs at risk. An important aspect of the software is that it does not require pre-processing of the DVH data. No differences were found between the SCRcalc results and those derived from manual calculations. The newly developed software offers the possibility to medical physicists and radiation oncologists to directly estimate the probability of radiotherapy-induced secondary malignancies for various organs at risk.
format Online
Article
Text
id pubmed-8989449
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Via Medica
record_format MEDLINE/PubMed
spelling pubmed-89894492022-04-08 A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses Tzanis, Eleftherios Mazonakis, Michael Damilakis, John Rep Pract Oncol Radiother Technical Note The aim of this study was the development of a software tool (SCRcalc) for the automatic estimation of the patient- and organ-specific cancer risk due to radiotherapy. SCRcalc was developed using the Python 3.8.7 programming language. It incorporates equations and parameters of mechanistic models for the calculation of the organ equivalent dose (OED), the excess absolute risk (EA R) and the lifetime attributable risk (LA R) of carcinogenesis for various organs due to radiotherapy. Data from differential dose-volume histograms, as defined by a treatment planning system, could be automatically inserted into the program. Eighteen different cancer risk estimates for various organs were performed of patients subjected to radiation therapy with conventional and modulated techniques. These software estimates were compared with manual calculations. SCRcalc was developed as a standalone executable program without any dependencies. It enables direct estimations of the OED and LAR for various organs at risk. An important aspect of the software is that it does not require pre-processing of the DVH data. No differences were found between the SCRcalc results and those derived from manual calculations. The newly developed software offers the possibility to medical physicists and radiation oncologists to directly estimate the probability of radiotherapy-induced secondary malignancies for various organs at risk. Via Medica 2022-03-22 /pmc/articles/PMC8989449/ /pubmed/35402031 http://dx.doi.org/10.5603/RPOR.a2022.0014 Text en © 2022 Greater Poland Cancer Centre https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
spellingShingle Technical Note
Tzanis, Eleftherios
Mazonakis, Michael
Damilakis, John
A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses
title A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses
title_full A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses
title_fullStr A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses
title_full_unstemmed A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses
title_short A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses
title_sort software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses
topic Technical Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989449/
https://www.ncbi.nlm.nih.gov/pubmed/35402031
http://dx.doi.org/10.5603/RPOR.a2022.0014
work_keys_str_mv AT tzaniseleftherios asoftwaretoolfororganspecificsecondcancerriskassessmentfromexposuretotherapeuticdoses
AT mazonakismichael asoftwaretoolfororganspecificsecondcancerriskassessmentfromexposuretotherapeuticdoses
AT damilakisjohn asoftwaretoolfororganspecificsecondcancerriskassessmentfromexposuretotherapeuticdoses
AT tzaniseleftherios softwaretoolfororganspecificsecondcancerriskassessmentfromexposuretotherapeuticdoses
AT mazonakismichael softwaretoolfororganspecificsecondcancerriskassessmentfromexposuretotherapeuticdoses
AT damilakisjohn softwaretoolfororganspecificsecondcancerriskassessmentfromexposuretotherapeuticdoses